Allogeneic blood stem cell transplantation with reduced conditioning has been proposed as a new, potentially curative treatment option for patients with rheumatoid arthritis (RA). We report a 60-year-old woman with RA and coexisting multiple myeloma who was treated with high-dose melphalan and autologous blood stem cell transplantation (BSCT) followed by a nonmyeloablative allogeneic BSCT from her healthy dizygotic twin brother. She achieved a complete remission of her RA after autologous BSCT, but relapsed early despite complete donor chimerism following successful allogeneic transplantation with reduced intensity conditioning. This case illustrates that allogeneic BSCT following nonmyeloablative conditioning may be an uncertain option for curing patients with RA.
rheumatoid arthritis; multiple myeloma; reduced-intensity conditioning; nonmyeloablative allogeneic blood stem cell transplantation Multiple myeloma (MM) is a neoplastic monoclonal proliferation of plasma cells, characterized by lytic bone lesions, plasma cell accumulation in the bone marrow, and the presence of monoclonal protein in the serum and urine. MM accounts for 1-2% of all cancers and is responsible for 20% of deaths from hematologic malignancies.
1 Myeloablative chemotherapy followed by autologous stem cell transplantation is an accepted treatment for myeloma, 2, 3 but most patients relapse and few achieve long-term remissions. Allogeneic blood stem cell transplantation (BSCT) has been shown to cure patients with MM by an immulologic graft-versus-myeloma (GvM) effect, but treatment-related mortality (TRM) has been as high as 50% with conventional myeloablative conditioning regimens. 4 New, reduced-intensity conditioning regimens have been developed to reduce TRM while preserving immunologic GvM reactions even in older patients.
Similar to the treatment of hematologic malignancies, there are several reports on long-term remissions of rheumatoid arthritis (RA) following allogeneic stem cell transplantation. [5] [6] [7] In addition to the immunosuppressive effects of high-dose chemotherapy and total body irradiation (TBI), some authors have postulated a graft-versusautoimmunity effect as an immunologic mechanism to cure patients with severe autoimmune disorders. Of immediate interest are the recent discussions on the use of allogeneic BSCT after dose reduced conditioning in patients with RA. 8 We report a patient with MM and coexisting RA who received an allogeneic BSCT with reduced intensity conditioning. To our knowledge, clinical experience with this new transplantation modality in patients with RA has not been published to date.
Case report
Seropositive RA was diagnosed in a 54-year old woman in 1995. The patient received radiosynoviorthesis of MTP IV, steroid injections in metatarsophalangeal joint V, proximal interphalangeal joint V in August 1995, as well as both wrists and the right elbow joint 2 years later. Therapy with gold was initiated in April 1998 but stopped after 4 weeks because of leukopenia. The patient was then treated with methotrexate (15 mg once a week) starting in July 1998, which was continued until January 2000.
In January 1996, IgG lambda MM (total protein 92 g/l, monoclonal IgG 31.9 g/l, bone marrow infiltration 50%, osteolytic lesions in both humeri) was diagnosed. The patient's condition remained stable until 1999 when treatment was initiated because of disease progression (total protein 107 g/l, IgG 59.8 g/l, bone marrow infiltration 60%). 2 /day 1-2) and granulocyte colony-stimulating factor (G-CSF 10 mg/kg, filgrastim, Amgen, Munich, Germany). In September 2000, the patient was treated with high-dose melphalan (100 mg/m autologous BSCT (2.7 Â 10 6 CD 34+/kg). According to EBMT criteria, 9 she achieved a partial remission (total protein 78 g/l, polyclonal IgG 14 g/l, positive immunofixation in blood, bone marrow plasma cell infiltration 4%).
In March 2001, the patient received G-CSF mobilized unselected allogeneic blood stem cells (5.6 Â 10 6 CD 34+/kg) from her healthy dizygotic HLA-identical twin brother after conditioning with fludarabine (30 mg/m 2 /day 1-3) and low dose TBI(200 cGy, single fraction). Cyclosporine A (6.25 mg/kg/day) and mycophenolate mofetil (15 mg/kg/day) were given post transplant. Single-tandemrepeat-PCR (STR-PCR) and XY-fluorescence in situ hybridization demonstrated complete donor chimerism in MNC, CD3+ cells and bone marrow by day +196. Negative immunofixation in blood and urine confirmed complete remission (CR) of the myeloma (total protein 77 g/l, polyclonal IgG 9.2 g/l, immunofixation negative). Immunosuppressive therapy was discontinued on day +190 after transplantation and reintroduced on day +230 to treat limited oral chronic graft-versus-host-disease (GvHD).
During the intensive treatment with chemotherapy from March 2000 until March 2001, the patient achieved a clinical and laboratory remission of her RA. The rheumatoid factor was negative. However, 10 months after allogeneic transplantation, she developed painful swellings of the right knee as well as both wrist joints and multiple metaphalangeal joints (Figure 1 ). Clinical reappearance of RA was accompanied by a positive rheumatioid factor (RF 51.5 IU/l) and a rise in c-reactive protein (CRP). Erosions resulting in reduction of the joint spaces and surface deformation of both wrists and cysts near the metaphalangeal joints IV and V of the right hand were documentated by X-ray. Treatment with steroids (prednisone 16 mg/ day) was initiated and the clinical symptoms improved within 12 days, but not the RF and CRP. STR-PCR of peripheral blood confirmed 100% donor hematopoiesis. At present, the patient is in CR of the MM with recurrent episodes of low-grade fever, joint swelling, and laboratory evidence of active smoldering RA. Figure 2 summerizes the course pre-and post reduced-intensity transplantation.
Discussion
RA is an immune-mediated disease that involves the joint synovium with inflammatory pannus that erodes cartilage and bone. Extra-articular symptoms may also occur, including rheumatoid nodules, vasculitis, and pulmonary interstitial fibrosis in rare cases. Immunosuppresive therapy and biologic response modifiers can slow down progression, but most patients suffer a painful disease course and develop physical impairment. Early reports have suggested that high-dose therapy and allogeneic stem cell transplantation may be able to cure RA. 10 Owing to the relatively high TRM of allogeneic BSCT, the first clinical trials in RA were conducted using high-dose immunosuppressive therapy and autologous BSCT. Burt et al 10 reported 30 patients receiving autologous HSCT following high-dose chemotherapy. Although these studies demonstrated good initial response to therapy, they also showed that CR is unusual and serologic or clinical relapse between 12 and 24 months is common. [11] [12] [13] [14] Since the early reports on long-term remissions of RA involved transplantation of allogeneic stem cells, several authors have postulated a graft-versus-autoimmunity effect (GvA) similar to the wellknown-graft-versus-leukemia (GvL) effect in hematological malignancies. [5] [6] [7] With the recent development of dosereduced conditioning regimens, the issue of allogeneic transplantation in RA became the subject of scientific discussions. These new 'minimal intensive' conditioning regimens rely on immunologic instead of cytotoxic mechanisms and are associated with a substantially lower risk of severe toxicities than BSCT-supported high-dose therapy approaches.
To our knowledge, the patient under discussion is the first with RA reported in the literature who received an allotransplant after minimal conditioning. The procedure resulted in a CR of the MM. However, the RA was only in remission during the period of intensive chemotherapy and autologous BSCT and recurred relatively early after nonmyeloablative allogeneic transplantation. The possible reasons for failure have been discussed in detail by McKendry et al. 15 In our opinion, there are two relevant aspects to be considered in our case. First, HLA-identical sibling donors of patients with RA may carry a genetic predisposition -the donor in our case was RF weakly positive (17.4 U/ml) but has not developed RA to date. Second, allogeneic BSCT after nonmyeloablative conditioning results in a variable period of mixed chimersim. In a state of mixed chimerism, residual recipient cells could sensitize HLA-identical donor T cells to perpetuate the immunologic imbalance underlying RA.
In conclusion, although at first glance promising, allogeneic BSCT following nonmyeloablative conditioning is associated with potentially severe toxicity and has a questionable curative potential.
